Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • NeuroPace's Change in Accured Expenses rose 1383.16% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 597027.03%. This contributed to the annual value of -$1.4 million for FY2024, which is 13694.27% down from last year.
  • As of Q3 2025, NeuroPace's Change in Accured Expenses stood at $2.6 million, which was up 1383.16% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, NeuroPace's Change in Accured Expenses ranged from a high of $2.6 million in Q3 2025 and a low of -$3.9 million during Q1 2024
  • In the last 5 years, NeuroPace's Change in Accured Expenses had a median value of $454000.0 in 2024 and averaged $347894.7.
  • In the last 5 years, NeuroPace's Change in Accured Expenses soared by 3997500.0% in 2023 and then plummeted by 36642.69% in 2024.
  • NeuroPace's Change in Accured Expenses (Quarter) stood at $423000.0 in 2021, then crashed by 132.15% to -$136000.0 in 2022, then surged by 941.91% to $1.1 million in 2023, then plummeted by 124.8% to -$284000.0 in 2024, then surged by 1033.1% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.2 million for Q2 2025, and -$2.3 million during Q1 2025.